60 Bottle Label (Sacubitrilvalsartan 24 26)
Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 62332-556
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 62332-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 7 (Sacubitrilvalsartan 7 Figure)
60 Bottle Label (Sacubitrilvalsartan 97103)
This text provides information about a medication called Sacubitril and Valsartan Tablets. Each tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage is not specified. The medicine should be stored at room temperature, away from moisture. The manufacturer is Alembic Pharmaceuticals Limited. The text also includes details about the dosage, manufacturing locations, and other relevant information.*
Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)
Figure 1 (Sacubitrilvalsartan Fig1)
This is a list of coadministered drugs with their geometric mean ratio and 90% confidence interval, along with a statement indicating the change relative to the reference drug. The list includes drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, Hertz, Metformin, Atorvastatin, and Sildenafil.*
Figure 3 (Sacubitrilvalsartan Fig3)
This is a detailed analysis of the time to first occurrence of cardiovascular death, heart failure hospitalizations, and occurrence of cardiovascular death in patients enrolled in the PARADIGM-HF study. The data shown includes hazard ratios and confidence intervals over different time intervals since randomization in days. The comparison is made between the effects of Enalapril, Sacubitril, and Valsartan on the mentioned occurrences. The graphs illustrate the trends and outcomes for each of the mentioned events.*
Figure 4 (Sacubitrilvalsartan Fig4)
This data table provides information on various subgroups within a study population, including demographic details, medical history, and treatment outcomes related to heart failure. The table displays percentages of the total population within each subgroup, along with specific data points such as age, gender, weight, race, region, NYHA class, estimated GFR, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension status, prior use of medications like ACE inhibitors and ARBs, prior hospitalizations for heart failure, time since diagnosis, cause of heart failure, and usage of specific medications like Sacubitril/Valsartan and Enalapril. Additionally, hazard ratios comparing the efficacy of Sacubitril/Valsartan versus Enalapril in heart failure treatment are provided in the table.*
Figure 6 (Sacubitrilvalsartan Figur6)
Figure 5 (Sacubitrilvalsartan Figure5)
This information seems to be related to a study or trial involving a medication called Sacubitril and Valsartan in patients with heart failure. The data is possibly showing the number of events or patients involved in the study over a period of time since randomization. The study may have looked at total heart failure hospitalizations and cardiovascular deaths in patients using this medication.*
60 Tablets Bottle Label (Sacubitrilvalsartan mg 49 51)
Structure (Sacubitrilvalsartan Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
